drugset / Trial / NCT06863194

Probiotic Supplementation and Disease Progression in CKD: A Randomized Trial

NCT06863194

Phase 1/2 Recruiting 72 enrolled Mansoura University
RandomizedParallel-groupTriple-blindPrevention

Summary

The goal of this clinical trial is to learn whether probiotic supplementation can slow disease progression in patients with moderate to severe chronic kidney disease (CKD). The trial will also assess the safety of probiotics in these patients. The main questions the study aims to answer are: Does probiotic supplementation improve kidney function by reducing serum creatinine levels and protein in urine? Does it reduce inflammation and metabolic imbalances in CKD patients? Does it affect gut microbiota composition and lower harmful toxins in the body? Is probiotic supplementation safe and well-tolerated in CKD patients? Participants will: Be randomly assigned to receive either probiotics or a placebo for 6 months. Have clinic visits every 6 months for checkups, blood tests, and urine tests. Be monitored for any side effects and changes in kidney function. Researchers will compare the probiotic group to the placebo group to determine whether probiotics are effective in slowing CKD progression.

Timeline

Start
2025-04-03
Primary completion
2025-10-03
Completion
2025-10-20

Drugs

EvaluationDrugModalityDoseRoute
Subject Lactobacillus plantarum Other / unclassified 1e+10 unknown